Syncona's Purespring raises £80m in new financing
Life science investor said its portfolio company Purespring Therapeutics, which focuses on gene therapies for kidney diseases, had raised £80m in an oversubscribed financing.
Syncona has committed £19.9m as part of a syndicate, led by Sofinnova, in collaboration with Gilde Healthcare, Forbion, and British Patient Capital, the company said on Wednesday.
The latest financing brings Purespring's total fundraising to date to around £115m. Proceeds will be used to advance its therapies pipeline and support the expected initiation of a phase I/II clinical trial in 2026 for its lead programme targeting IgA Nephropathy (IgAN), a chronic kidney disease principally affecting young adults.
Reporting by Frank Prenesti for Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.